Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited

Bibliography

• Andrews G, Sanderson K, Corry J, Lapsley HM. Using epidemiological data to model efficiency in reducing the burden of depression. J Ment Health Policy Econ 2000;3:175-86
   PubMedGoogle Scholar
• Kulkarni SK, Dhir A. Current investigational drugs for major depression. Expert Opin Investig Drugs 2009;18:767-88
   PubMed Web of Science ®Google Scholar
• El Mansari M, Guiard BP, Chernoloz O, Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 2010;16:1-17
   PubMed Web of Science ®Google Scholar
• Di Giovanni G, Esposito E, Di Matteo V. Role of serotonin in central dopamine dysfunction. CNS Neurosci Ther 2010;16:179-94
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007;64:327-37
   PubMed Web of Science ®Google Scholar
• Millan MJ. Dual-and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurother 2009;6:53-77
   PubMed Web of Science ®Google Scholar
• Skolnick P, Krieter P, Tizzano J, Preclinical and clinical pharmacology of DOV 216,303, a “triple” reuptake inhibitor. CNS Drug Rev 2006;12:123-34
   PubMedGoogle Scholar
• Skolnick P, Popik P, Janowsky A, “Broad spectrum” antidepressants: is more better for the treatment of depression? Life Sci 2003;73:3175-9
   PubMed Web of Science ®Google Scholar
• Chen Z, Yang J, Tobak A. Designing new treatments for depression and anxiety. IDrugs 2008;11:189-97
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Association, Washington, DC; 1994
   Google Scholar
• Horwath E, Johnson J, Weissman MM, Hornig CD. The validity of major depression with atypical features based on a community study. J Affect Disord 1992;26:117-25
   PubMed Web of Science ®Google Scholar
• Lamers F, De Jonge P, Nolen WA, Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 2010;71:1582-9
   PubMed Web of Science ®Google Scholar
• Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002;7:254-75
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Text revision. American Psychiatric Association, Washington, DC; 2000
   Google Scholar
• Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc Assoc Am Phys 1999;111:22-34
   PubMedGoogle Scholar
• Baldwin DS, Papakostas GI. Symptoms of fatigue and sleepiness in major depressive disorder. J Clin Psychiatry 2006;67:9-15
   PubMed Web of Science ®Google Scholar
• Levitan RD, Lesage A, Parikh SV, Reversed neurovegetative symptoms of depression: a community study of Ontario. Am J Psychiatry 1997;154:934-40
   PubMed Web of Science ®Google Scholar
• Kirsch I, Deacon BJ, Huedo-Medina TB, Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:260-8
   Web of Science ®Google Scholar
• Fournier JC, DeRubeis RJ, Hollon SD, Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53
   PubMed Web of Science ®Google Scholar
• Lichtenberg P, Belmaker RH. Subtyping major depressive disorder. Psychother Psychosom 2010;79:131-5
   PubMed Web of Science ®Google Scholar
• Fuster JM. The prefrontal cortex-an update: time is of the essence. Neuron 2001;30:319-33
   PubMed Web of Science ®Google Scholar
• Mayberg HS, Liotti M, Brannan SK, Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999;156:675-82
   PubMed Web of Science ®Google Scholar
• Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacol 2010;35:192-216
   PubMed Web of Science ®Google Scholar
• Davidson RJ, Lewis DA, Alloy LB, Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry 2002;52:478-502
   PubMed Web of Science ®Google Scholar
• Koenigs M, Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res 2009;201:239-43
   PubMed Web of Science ®Google Scholar
• Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacol 2010;35:217-38
   PubMed Web of Science ®Google Scholar
• Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 2009;32:267-87
   PubMed Web of Science ®Google Scholar
• Molliver ME. Serotonergic neuronal systems: what their anatomic organization tells us about function. J Clin Psychopharmacol 1987;7:3S-23S
   PubMed Web of Science ®Google Scholar
• Sastry BS, Phillis JW. Inhibition of cerebral cortical neurones by a 5-hydroxytryptaminergic pathway from median raphe nucleus. Can J Physiol Pharmacol 1977;55:737-43
   PubMed Web of Science ®Google Scholar
• Dillier N, Laszlo J, Muller B, Activation of an inhibitory noradrenergic pathway projecting from the locus coeruleus to the cingulate cortex of the rat. Brain Res 1978;154:61-8
   PubMed Web of Science ®Google Scholar
• Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 2003;42:33-84
   PubMed Web of Science ®Google Scholar
• Arnsten AF. Through the looking glass: differential noradrenergic modulation of prefrontal cortical function. Neural Plast 2000;7:133-46
   PubMed Web of Science ®Google Scholar
• Wong ML, Kling MA, Munson PJ, Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA 2000;97:325-30
   PubMed Web of Science ®Google Scholar
• Williams SM, Goldman-Rakic PS. Widespread origin of the primate mesofrontal dopamine system. Cereb Cortex 1998;8:321-45
   PubMed Web of Science ®Google Scholar
• Sesack SR, Hawrylak VA, Matus C, Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 1998;18:2697-708
   PubMed Web of Science ®Google Scholar
• Daws LC. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol Ther 2009;121:89-99
   PubMed Web of Science ®Google Scholar
• Berridge KC, Kringelbach ML. Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacol 2008;199:457-80
   PubMed Web of Science ®Google Scholar
• Marinelli M, Piazza PV. Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur J Neurosci 2002;16:387-94
   PubMed Web of Science ®Google Scholar
• Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med 2005;353:1711-23
   PubMed Web of Science ®Google Scholar
• Leshner AI, Koob GF. Drugs of abuse and the brain. Proc Assoc Am Phys 1999;111:99-108
   PubMedGoogle Scholar
• Tremblay LK, Naranjo CA, Cardenas L, Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry 2002;59:409-16
   PubMed Web of Science ®Google Scholar
• Tremblay LK, Naranjo CA, Graham SJ, Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry 2005;62:1228-36
   PubMed Web of Science ®Google Scholar
• Saper CB, Chou TC, Elmquist JK. The need to feed: homeostatic and hedonic control of eating. Neuron 2002;36:199-211
   PubMed Web of Science ®Google Scholar
• Zheng H, Berthoud HR. Eating for pleasure or calories. Curr Opin Pharmacol 2007;7:607-12
   PubMed Web of Science ®Google Scholar
• Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 2010;13:635-41
   PubMed Web of Science ®Google Scholar
• Adamec RE. Hypothalamic and extrahypothalamic substrates of predatory attack. Suppression and the influence of hunger. Brain Res 1976;106:57-69
   PubMed Web of Science ®Google Scholar
• Mignot E. A commentary on the neurobiology of the hypocretin/orexin system. Neuropsychopharmacol 2001;25:S5-13
   PubMedGoogle Scholar
• Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001;24:726-31
   PubMed Web of Science ®Google Scholar
• Wisor JP, Nishino S, Sora I, Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-94
   PubMed Web of Science ®Google Scholar
• Peyron C, Tighe DK, Van Den Pol AN, Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015
   PubMed Web of Science ®Google Scholar
• Bittencourt JC, Presse F, Arias C, The melanin-concentrating hormone system of the rat brain: an immuno-and hybridization histochemical characterization. J Comp Neurol 1992;319:218-45
   PubMed Web of Science ®Google Scholar
• Strecker RE, Nalwalk J, Dauphin LJ, Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleep-wakefulness and prolonged wakefulness: an in vivo microdialysis study. Neurosci 2002;113:663-70
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Crits-Christoph P, Evans DL, Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2007;27:614-19
   PubMed Web of Science ®Google Scholar
• Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 2003;339:143-6
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Nutt DJ, Hallett LA, Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006;60:1350-5
   PubMed Web of Science ®Google Scholar
• Flint AJ, Black SE, Campbell-Taylor I, Abnormal speech articulation, psychomotor retardation, and subcortical dysfunction in major depression. J Psychiatr Res 1993;27:309-19
   PubMed Web of Science ®Google Scholar
• Stahl SM, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry 2003;64:6-17
   Web of Science ®Google Scholar
• Banki CM. Correlation between cerebrospinal fluid amine metabolites and psychomotor activity in affective disorders. J Neurochem 1977;28:255-7
   PubMed Web of Science ®Google Scholar
• Korf J, Van Praag HM. Retarded depression and the dopamine metabolism. Psychopharmacology 1971;19:199-203
   PubMedGoogle Scholar
• Praag HM, Korf J, Lakke J, Schut T. Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders. Psychol Med 1975;5:138-46
   PubMed Web of Science ®Google Scholar
• Stein DJ. Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry. CNS Spectr 2008;13:561-5
   PubMed Web of Science ®Google Scholar
• Carroll BJ, Feinberg M, Greden JF, A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981;38:15-22
   PubMed Web of Science ®Google Scholar
• Mitchell P, Hadzi Pavlovic D, Parker G, Depressive psychomotor disturbance, cortisol, and dexamethasone. Biol Psychiatry 1996;40:941-50
   PubMed Web of Science ®Google Scholar
• Martinot M, Bragulat V, Artiges E, Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry 2001;158:314-16
   PubMed Web of Science ®Google Scholar
• Bragulat V, Paillere-Martinot ML, Artiges E, Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis. Psychiatry Res 2007;154:115-24
   PubMed Web of Science ®Google Scholar
• Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003;4:819-28
   PubMed Web of Science ®Google Scholar
• Mann JJ, Henteleff RA, Lagattuta TF, Lower 3H-paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high affinity, non-transporter sites. J Neural Transm 1996;103:1337-50
   PubMed Web of Science ®Google Scholar
• Olivier B. Serotonin and aggression. Ann N Y Acad Sci 2004;1036:382-92
   PubMed Web of Science ®Google Scholar
• Gonzalez LE, Quinonez B, Rangel A, Tonic and phasic alteration in amygdala 5-HT, glutamate and GABA transmission after prefrontal cortex damage in rats. Brain Res 2004;1005:154-63
   PubMed Web of Science ®Google Scholar
• Brown RP, Stoll PM, Stokes PE, Adrenocortical hyperactivity in depression: effects of agitation, delusions, melancholia, and other illness variables. Psychiatry Res 1988;23:167-78
   PubMed Web of Science ®Google Scholar
• Fawcett J, Busch KA, Jacobs D, Suicide: a four-pathway clinical-biochemical model. Ann N Y Acad Sci 1997;836:288-301
   PubMed Web of Science ®Google Scholar
• Pitchot W, Reggers J, Pinto E, Reduced dopaminergic activity in depressed suicides. Psychoneuroendocrinol 2001;26:331-5
   PubMed Web of Science ®Google Scholar
• Roy A. Hypothalamic-pituitary-adrenal axis function and suicidal behavior in depression. Biol Psychiatry 1992;32:812-16
   PubMed Web of Science ®Google Scholar
• Watson S, Young AH. Reduced dopaminergic activity in depressed suicides. Psychoneuroendocrinol 2001;26:759-60
   Web of Science ®Google Scholar
• Li CT, Lin CP, Chou KH, Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study. Neuroimage 2010;50:347-56
   PubMed Web of Science ®Google Scholar
• Rypma B, D'Esposito M. The roles of prefrontal brain regions in components of working memory: effects of memory load and individual differences. Proc Natl Acad Sci U S A 1999;96:6558-63
   PubMed Web of Science ®Google Scholar
• Fuster JM. The prefrontal cortex and its relation to behavior. Prog Brain Res 1991;87:201-11
   PubMed Web of Science ®Google Scholar
• Fuster JM. Memory networks in the prefrontal cortex. Prog Brain Res 2000;122:309-16
   PubMed Web of Science ®Google Scholar
• Morrison PD, Murray RM. From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophr Bull 2009;35:668-74
   PubMed Web of Science ®Google Scholar
• Duval F, Mokrani MC, Crocq MA, Dopaminergic function and the cortisol response to dexamethasone in psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:207-25
   PubMed Web of Science ®Google Scholar
• Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med 2011;73:114-26
   PubMed Web of Science ®Google Scholar
• Hache G, Coudore F, Gardier AM, Guiard BP. Monoaminergic antidepressants in the relief of pain: potential therapeutic utility of triple reuptake inhibitors (TRIs). Pharma 2011;4:285-342
   Google Scholar
• Basile AS, Janowsky A, Golembiowska K, Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther 2007;32:1208-25
   Google Scholar
• Weber MM, Emrich HM. Current and historical concepts of opiate treatment in psychiatric disorders. Int Clin Psychopharmacol 1988;3:255-66
   PubMed Web of Science ®Google Scholar
• Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 1958;115:459-64
   PubMed Web of Science ®Google Scholar
• Kuhn R. Treatment of depressive states with an iminodibenzyl derivative (G 22355). Schweiz Med Wochenschr 1957;87:1135-40
   PubMedGoogle Scholar
• Axelrod J, Whitby LG, Hertting G. Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues. Sci 1961;133:383-4
   PubMed Web of Science ®Google Scholar
• Axelrod J, Whitby LG, Hertting G, Kopin IL. Studies on the metabolism of catecholamines. Circ Res 1961;9:715-20
   PubMed Web of Science ®Google Scholar
• Thase ME, Frank E, Mallinger AG, Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11
   PubMed Web of Science ®Google Scholar
• Nandagopal JJ, DelBello MP. Selegiline transdermal system: a novel treatment option for major depressive disorder. Expert Opin Pharmacother 2009;10:1665-73
   PubMed Web of Science ®Google Scholar
• Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-22
   PubMed Web of Science ®Google Scholar
• Guiard BP, El Mansari M, Blier P. Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus coeruleus, and dorsal hippocampus. Mol Pharmacol 2008;74:1463-75
   PubMed Web of Science ®Google Scholar
• Guiard BP, El Mansari M, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets 2009;10:1069-84
   PubMed Web of Science ®Google Scholar
• Boyer P, Tassin JP, Falissart B, Troy S. Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression. J Clin Pharm Ther 2000;25:363-71
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol 2005;8:93-105
   PubMed Web of Science ®Google Scholar
• Kopta SM, Howard KI, Lowry JL, Beutler LE. Patterns of symptomatic recovery in psychotherapy. J Consult Clin Psychol 1994;62:1009-16
   PubMed Web of Science ®Google Scholar
• Opdyke KS, Reynolds CF III, Frank E, Effect of continuation treatment on residual symptoms in late-life depression: how well is “well”? Depress Anxiety 1996;4:312-19
   PubMedGoogle Scholar
• Moos RH, Cronkite RC. Symptom-based predictors of a 10-year chronic course of treated depression. J Nerv Ment Dis 1999;187:360-8
   PubMed Web of Science ®Google Scholar
• Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacol 1995;12:185-19
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997;11:S9-15
   PubMed Web of Science ®Google Scholar
• Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998;59:8-10
   PubMed Web of Science ®Google Scholar
• Chuluunkhuu G, Nakahara N, Yanagisawa S, Kamae I. The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes. Kobe J Med Sci 2008;54:E147-58
   PubMedGoogle Scholar
• Papakostas GI, Nelson JC, Kasper S, Moller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2008;18:122-7
   PubMed Web of Science ®Google Scholar
• Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9:139-43
   PubMed Web of Science ®Google Scholar
• Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62:869-77
   PubMed Web of Science ®Google Scholar
• Kasper S, Pletan Y, Solles A, Tournoux A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 1996;11:35-9
   PubMed Web of Science ®Google Scholar
• Lopez-Ibor J, Guelfi JD, Pletan Y, Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996;11:41-6
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41
   PubMed Web of Science ®Google Scholar
• Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732-47
   PubMed Web of Science ®Google Scholar
• Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59:1151-9
   PubMed Web of Science ®Google Scholar
• Nutt D, Demyttenaere K, Janka Z, The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007;21:461-71
   PubMed Web of Science ®Google Scholar
• Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiol 1999;39:25-32
   PubMed Web of Science ®Google Scholar
• Cassano P, Lattanzi L, Fava M, Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005;50:357-60
   PubMed Web of Science ®Google Scholar
• Corrigan MH, Denahan AQ, Wright CE, Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65
   PubMed Web of Science ®Google Scholar
• Guyon A, Assouly-Besse F, Biala G, Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats. Psychopharmacol 1993;110:460-6
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-6
   PubMed Web of Science ®Google Scholar
• Gupta S, Vincent JL, Frank B. Pramipexole: augmentation in the treatment of depressive symptoms. CNS Spectr 2006;11:172-5
   PubMed Web of Science ®Google Scholar
• Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 2006;248:266-70
   PubMed Web of Science ®Google Scholar
• Raskin S, Durst R. Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. Med Hypotheses 2010;75:544-6
   PubMed Web of Science ®Google Scholar
• Hansard MJ, Smith LA, Jackson MJ, Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther 2002;303:952-8
   PubMed Web of Science ®Google Scholar
• Schultz W. Dopamine signals for reward value and risk: basic and recent data. Behav Brain Funct 2010;6:1-9
   PubMedGoogle Scholar
• Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci 2007;30:259-88
   PubMed Web of Science ®Google Scholar
• Floresco SB, West AR, Ash B, Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 2003;6:968-73
   PubMed Web of Science ®Google Scholar
• Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neurosci 1991;41:1-24
   PubMed Web of Science ®Google Scholar
• Leknes S, Tracey I. A common neurobiology for pain and pleasure. Nat Rev Neurosci 2008;9:314-20
   PubMed Web of Science ®Google Scholar
• Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185:1-10
   PubMed Web of Science ®Google Scholar
• Krystal JH, Sanacora G, Blumberg H, Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 2002;7:S71-80
   PubMed Web of Science ®Google Scholar
• Brambilla P, Perez J, Barale F, GABAergic dysfunction in mood disorders. Mol Psychiatry 2003;8:721-37
   PubMed Web of Science ®Google Scholar
• Stewart CA, Reid IC. Antidepressant mechanisms: functional and molecular correlates of excitatory amino acid neurotransmission. Mol Psychiatry 2002;7:S15-22
   PubMedGoogle Scholar
• Sanacora G, Gueorguieva R, Epperson CN, Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004;61:705-13
   PubMed Web of Science ®Google Scholar
• Merali Z, Du L, Hrdina P, Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 2004;24:1478-85
   PubMed Web of Science ®Google Scholar
• Cryan JF, Kaupmann K. Don't worry ‘B’ happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci 2005;26:36-43
   PubMed Web of Science ®Google Scholar
• McEwen BS, Chattarji S, Diamond DM, The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010;15:237-49
   PubMed Web of Science ®Google Scholar
• Cheetham SC, Crompton MR, Katona CL, Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Res 1988;460:114-23
   PubMed Web of Science ®Google Scholar
• Holemans S, De Paermentier F, Horton RW, NMDA glutamatergic receptors, labelled with [3H]MK-801, in brain samples from drug-free depressed suicides. Brain Res 1993;616:138-43
   PubMed Web of Science ®Google Scholar
• Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995;675:157-64
   PubMed Web of Science ®Google Scholar
• Noga JT, Hyde TM, Herman MM, Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse 1997;27:168-76
   PubMed Web of Science ®Google Scholar
• Choudary PV, Molnar M, Evans SJ, Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 2005;102:15653-8
   PubMed Web of Science ®Google Scholar
• Sequeira A, Mamdani F, Ernst C, Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 2009;4:1-14
   Google Scholar
• Horn DI, Yu C, Steiner J, Glutamatergic and resting-state functional connectivity correlates of severity in major depression-the role of pregenual anterior cingulate cortex and anterior insula. Front Syst Neurosci 2010;4:1-10
   PubMedGoogle Scholar
• Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000;48:813-29
   PubMed Web of Science ®Google Scholar
• Sanacora G, Gueorguieva R, Epperson CN, Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004;61:705-13
   PubMed Web of Science ®Google Scholar
• Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185:1-10
   PubMed Web of Science ®Google Scholar
• Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995;675:157-64
   PubMed Web of Science ®Google Scholar
• Pittaluga A, Raiteri L, Longordo F, Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacol 2007;53:27-36
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Du J, Quiroz J, Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 2003;1003:273-91
   PubMed Web of Science ®Google Scholar
• Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008;7:426-37
   PubMed Web of Science ®Google Scholar
• Racagni G, Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci 2008;10:385-400
   PubMedGoogle Scholar
• Wang SJ, Su CF, Kuo YH. Fluoxetine depresses glutamate exocytosis in the rat cerebrocortical nerve terminals (synaptosomes) via inhibition of P/Q-type Ca2+ channels. Synapse 2003;48:170-7
   PubMed Web of Science ®Google Scholar
• Bonanno G, Giambelli R, Raiteri L, Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005;25:3270-9
   PubMed Web of Science ®Google Scholar
• Lin TY, Yang TT, Lu CW, Wang SJ. Inhibition of glutamate release by bupropion in rat cerebral cortex nerve terminals. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:598-606
   PubMed Web of Science ®Google Scholar
• Michael-Titus AT, Bains S, Jeetle J, Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex – a possible mechanism of neuroprotection in major depression? Neurosci 2000;100:681-4
   PubMed Web of Science ®Google Scholar
• Tokarski K, Bobula B, Wabno J, Hess G. Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. Neurosci 2008;153:789-95
   PubMed Web of Science ®Google Scholar
• Musazzi L, Milanese M, Farisello P, Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS One 2010;5:1-11
   Google Scholar
• Tordera RM, Pei Q, Sharp T. Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment. J Neurochem 2005;94:875-83
   PubMed Web of Science ®Google Scholar
• Moutsimilli L, Farley S, Dumas S, Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacol 2005;49:890-900
   PubMed Web of Science ®Google Scholar
• Nowak G, Trullas R, Layer RT, Adaptive changes in the N-methyl-d-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993;265:1380-6
   PubMed Web of Science ®Google Scholar
• Paul IA, Layer RT, Skolnick P, Nowak G. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur J Pharmacol 1993;247:305-11
   PubMed Web of Science ®Google Scholar
• Skolnick P, Layer RT, Popik P, Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996:29:23-6
   PubMed Web of Science ®Google Scholar
• Nowak G, Legutko B, Skolnick P, Popik P. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur J Pharmacol 1998;342:367-70
   PubMed Web of Science ®Google Scholar
• Ryan B, Musazzi L, Mallei A, Remodelling by early-life stress of NMDA receptor-dependent synaptic plasticity in a gene-environment rat model of depression. Int J Neuropsychopharmacol 2008;31:1-7
   Google Scholar
• Jay TM, Gurden H, Yamaguchi T. Rapid increase in PKA activity during long-term potentiation in the hippocampal afferent fibre system to the prefrontal cortex in vivo. Eur J Neurosci 1998;10:3302-6
   PubMed Web of Science ®Google Scholar
• Jay TM. Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol 2003;69:375-90
   PubMed Web of Science ®Google Scholar
• Kruse MS, Premont J, Krebs MO, Jay TM. Interaction of dopamine D1 with NMDA NR1 receptors in rat prefrontal cortex. Eur Neuropsychopharmacol 2009;19:296-304
   PubMed Web of Science ®Google Scholar
• Lavergne F, Jay TM. A new strategy for antidepressant prescription. Front Neurosci 2010;4:1-13
   PubMedGoogle Scholar
• Gao C, Wolf ME. Dopamine receptors regulate NMDA receptor surface expression in prefrontal cortex neurons. J Neurochem 2008;106:2489-501
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu R-J, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Sci 2010;329:959-64
   PubMed Web of Science ®Google Scholar
• Barbon A, Popoli M, La Via L, Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainite receptors by antidepressant drugs Biol Psychiatry 2006;59:713-20
   PubMed Web of Science ®Google Scholar
• Venningsson P, Tzavara ET, Witkin JM, Involvement of striatal and extrastriatal DARPP−32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A 2002;99:3182-7
   PubMed Web of Science ®Google Scholar
• Martinez-Turrillas R, Del Rio J, Frechilla, D. Neuronal proteins involved in synaptic targeting of AMPA receptors in rat hippocampus by antidepressant drugs. Biochem Biophys Res Commun 2007;353:750-5
   PubMed Web of Science ®Google Scholar
• Lauterborn JC, Lynch G, Vanderklish P, Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 2000;20:8-21
   PubMed Web of Science ®Google Scholar
• Sun X, Zhao Y, Wolf ME. Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons. J Neurosci 2005;25:7342-51
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-52
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-42
   PubMed Web of Science ®Google Scholar
• Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997;12:S7-14
   PubMed Web of Science ®Google Scholar
• Meyer JH, Goulding VS, Wilson AA, Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacol 2002;163:102-5
   PubMed Web of Science ®Google Scholar
• Learned-Coughlin SM, Bergstrom M, Savitcheva I, In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003;54:800-5
   PubMed Web of Science ®Google Scholar
• Meyer JH, Wilson AA, Sagrati S, Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-35
   PubMed Web of Science ®Google Scholar
• Prins J, Denys DA, Westphal KG, The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats. Eur J Pharmacol 2010;633:55-61
   PubMed Web of Science ®Google Scholar
• Caldarone BJ, Paterson NE, Zhou J, The novel triple reuptake inhibitor, JZAD-IV-22, exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties. J Pharmacol Exp Ther 2010;335:762-70
   PubMed Web of Science ®Google Scholar
• Prins J, Westphal KG, Korte-Bouws GA, The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats. Pharmacol Biochem Behav 2011;97:444-52
   PubMed Web of Science ®Google Scholar
• Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370
   PubMed Web of Science ®Google Scholar
• Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997;8:523-32
   PubMed Web of Science ®Google Scholar
• Katz MM, Tekell JL, Bowden CL, Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacol 2004;29:566-79
   PubMed Web of Science ®Google Scholar
• Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36
   PubMedGoogle Scholar
• Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacol 1988;94:147-60
   PubMed Web of Science ®Google Scholar
• West AP. Neurobehavioral studies of forced swimming: the role of learning and memory in the forced swim test. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:863-77
   PubMed Web of Science ®Google Scholar
• Korte SM, De Kloet ER, Buwalda B, Antisense to the glucocorticoid receptor in hippocampal dentate gyrus reduces immobility in forced swim test. Eur J Pharmacol 1996;301:19-25
   PubMed Web of Science ®Google Scholar
• Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiatry 2010;9:155-61
   PubMed Web of Science ®Google Scholar
• Korte SM. Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci Biobehav Rev 2001;25:117-42
   PubMed Web of Science ®Google Scholar
• LeDoux JE. Emotional memory systems in the brain. Behav Brain Res 1993;58:69-79
   PubMed Web of Science ®Google Scholar
• Joels M, Hesen W, De Kloet ER. Mineralocorticoid hormones suppress serotonin-induced hyperpolarization of rat hippocampal CA1 neurons. J Neurosci 1991;11:2288-94
   PubMed Web of Science ®Google Scholar
• File SE, Gonzalez LE, Andrews N. Comparative study of pre-and postsynaptic 5-HT1A receptor modulation of anxiety in two ethological animal tests. J Neurosci 1996;16:4810-15
   PubMed Web of Science ®Google Scholar
• Flint J. Animal models of anxiety and their molecular dissection. Semin Cell Dev Biol 2003;14:37-42
   PubMed Web of Science ®Google Scholar
• Drugan RC, Macomber H, Warner TA. Intermittent and continuous swim stress-induced behavioral depression: sensitivity to norepinephrine- and serotonin-selective antidepressants. Psychopharmacol 2010;212:85-91
   PubMed Web of Science ®Google Scholar
• Willner P. The validity of animal models of depression. Psychopharmacol 1984;83:1-16
   PubMed Web of Science ®Google Scholar
• Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 1992;16:525-34
   PubMed Web of Science ®Google Scholar
• Der-Avakian A, Markou A. Neonatal maternal separation exacerbates the reward-enhancing effect of acute amphetamine administration and the anhedonic effect of repeated social defeat in adult rats. Neurosci 2010;170:1189-98
   PubMed Web of Science ®Google Scholar
• Ruis MA, Te Brake JH, Buwalda B, Housing familiar male wildtype rats together reduces the long-term adverse behavioural and physiological effects of social defeat. Psychoneuroendocrinology 1999;24:285-300
   PubMed Web of Science ®Google Scholar
• Markou A, Koob GF. Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav 1992;51:111-19
   PubMed Web of Science ®Google Scholar
• Willner P, Towell A, Sampson D, Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacol 1987;93:358-64
   PubMed Web of Science ®Google Scholar
• Snoeren EM, Chan JS, De Jong TR, A new female rat animal model for hypoactive sexual desire disorder; behavioral and pharmacological evidence. J Sex Med 2010;8:44-56
   PubMed Web of Science ®Google Scholar
• Chan JS, Waldinger MD, Olivier B, Oosting RS. Drug-induced sexual dysfunction in rats. Curr Protoc Neurosci 2010; Chapter 9:Unit 9.34
   Google Scholar
• Breuer ME, Groenink L, Oosting RS, Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats. Biol Psychiatry 2007;61:990-5
   PubMed Web of Science ®Google Scholar
• De Bodinat C, Guardiola-Lemaitre B, Mocaer E, Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010;9:628-42, Erratum in: Nat Rev Drug Discov 2010;9:743
   PubMed Web of Science ®Google Scholar
• Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacol 2000;23:477-501
   PubMed Web of Science ®Google Scholar
• Dantzer R, O'Connor JC, Freund GG, From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56
   PubMed Web of Science ®Google Scholar
• Wood PB. Mesolimbic dopaminergic mechanisms and pain control. Pain 2006;120:230-4
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Logan J, Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009;301:1148-54
   PubMed Web of Science ®Google Scholar
• Paterson NE, Fedolak A, Olivier B, Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav 2010;95:449-56
   PubMed Web of Science ®Google Scholar
• Bevins RA, Wilkinson JL, Palmatier MI, Characterization of nicotine's ability to serve as a negative feature in a Pavlovian appetitive conditioning task in rats. Psychopharmacol 2006;184:470-81
   Web of Science ®Google Scholar
• Bergman J, Madras BK, Johnson SE, Spealman RD. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 1989;251:150-5
   PubMed Web of Science ®Google Scholar
• Nicholson KL, Balster RL, Golembiowska K, Preclinical evaluation of the abuse potential of the analgesic bicifadine. J Pharmacol Exp Ther 2009;330:236-48
   PubMed Web of Science ®Google Scholar
• Cousins MS, Stamat HM, De Wit H. Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacol 2001;157:243-53
   PubMed Web of Science ®Google Scholar
• Griffith JD, Carranza J, Griffith C, Miller LL. Bupropion: clinical assay for amphetamine-like abuse potential. J Clin Psychiatry 1983;44:206-8
   PubMed Web of Science ®Google Scholar
• Zernig G, De Wit H, Telser S, Subjective effects of slow-release bupropion versus caffeine as determined in a quasi-naturalistic setting. Pharmacol 2004;70:206-15
   PubMed Web of Science ®Google Scholar
• Schoedel KA, Meier D, Chakraborty B, Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther 2010;88:69-78
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fischman MW, Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997;386:827-30
   PubMed Web of Science ®Google Scholar
• Gardner EL, Liu X, Paredes W, A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction. Neuropharmacol 2006;51:993-1003
   PubMed Web of Science ®Google Scholar
• Drevets WC, Price JL, Simpson JR Jr, Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824-7
   PubMed Web of Science ®Google Scholar
• Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001;7:541-7
   PubMed Web of Science ®Google Scholar
• Manji HK, Quiroz JA, Sporn J, Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003;53:707-42
   PubMed Web of Science ®Google Scholar
• McEwen BS, Chattarji S. Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine. Eur Neuropsychopharmacol 2004;14:S497-502
   PubMedGoogle Scholar
• Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacol 2008;33:88-109
   PubMed Web of Science ®Google Scholar
• Brilman EI, Ormel J. Life events, difficulties and onset of depressive episodes in later life. Psychol Med 2001;31:859-69
   PubMed Web of Science ®Google Scholar
• Sandi C, Richter-Levin G. From high anxiety trait to depression: a neurocognitive hypothesis. Trends Neurosci 2009;32:312-20
   PubMed Web of Science ®Google Scholar
• Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000;48:755-65
   PubMed Web of Science ®Google Scholar
• McEwen BS. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann N Y Acad Sci 2001;933:265-77
   PubMed Web of Science ®Google Scholar
• Venero C, Borrell J. Rapid glucocorticoid effects on excitatory amino acid levels in the hippocampus: a microdialysis study in freely moving rats. Eur J Neurosci 1999;11:2465-73
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Bolinao ML, Stein-Behrens B, Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res 1994;655:251-4
   PubMed Web of Science ®Google Scholar
• Stein-Behrens BA, Lin WJ, Sapolsky RM. Physiological elevations of glucocorticoids potentiate glutamate accumulation in the hippocampus. J Neurochem 1994;63:596-602
   PubMed Web of Science ®Google Scholar
• Olijslagers JE, De Kloet ER, Elgersma Y, Rapid changes in hippocampal CA1 pyramidal cell function via pre-as well as postsynaptic membrane mineralocorticoid receptors. Eur J Neurosci 2008;27:2542-50
   PubMed Web of Science ®Google Scholar
• Karst H, Berger S, Turiault M, Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc Natl Acad Sci U S A 2005;102:19204-7
   PubMed Web of Science ®Google Scholar
• Yuen EY, Liu W, Karatsoreos IN, Acute stress enhances glutamatergic transmission in prefrontal cortex and facilitates working memory. Proc Natl Acad Sci U S A 2009;106:14075-9
   PubMed Web of Science ®Google Scholar
• Lee KH, Park CE, Min KH, Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett 2001;20:5567-71
   Google Scholar
• Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig 2008;5:142-7
   PubMed Web of Science ®Google Scholar
• McMillen BA, Shank JE, Jordan KB, Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat. Alcohol Clin Exp Res 2007;31:1866-71
   PubMed Web of Science ®Google Scholar
• Breuer ME, Chan JS, Oosting RS, The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur Neuropsychopharmacol 2008;18:908-16
   PubMed Web of Science ®Google Scholar
• Beer B, Stark J, Krieter P, DOV 216,303, a “triple” reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol 2004;44:1360-7
   PubMed Web of Science ®Google Scholar
• Chen Z, Skolnick P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs 2007;16:1365-77
   PubMed Web of Science ®Google Scholar
• Skolnick P, Basile AS. Triple reuptake inhibitors (“broad spectrum” antidepressants). CNS Neurol Disord Drug Targets 2007;6:141-9
   PubMedGoogle Scholar
• Guiard BP, Chenu F, Mansari ME, Blier P. Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons. Int J Neuropsychopharmacol 2011;14:211-23
   PubMed Web of Science ®Google Scholar
• Skolnick P, Popik P, Janowsky A, Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol 2003;461:99-104
   PubMed Web of Science ®Google Scholar
• Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord 2007;22:359-6
   PubMed Web of Science ®Google Scholar
• Hansen HH, Hansen G, Tang-Christensen M, The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 2010;636:88-95
   PubMed Web of Science ®Google Scholar
• Larsen MH, Rosenbrock H, Sams-Dodd F, Mikkelsen JD. Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. Eur J Pharmacol 2007;555:115-21
   PubMed Web of Science ®Google Scholar
• Rascol O, Poewe W, Lees A, Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 2008;65:577-83
   PubMed Web of Science ®Google Scholar
• Basile AS, Janowsky A, Golembiowska K, Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther 2007;321:1208-25
   PubMed Web of Science ®Google Scholar
• Aluisio L, Lord B, Barbier AJ, In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. Eur J Pharmacol 2008;587:141-6
   PubMed Web of Science ®Google Scholar
• Maryanoff BE, McComsey DF, Gardocki JF, Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships. J Med Chem 1987;30:1433-54
   PubMed Web of Science ®Google Scholar
• Shaw AM, Boules M, Zhang Y, Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur J Pharmacol 2007;555:30-6
   PubMed Web of Science ®Google Scholar
• Liang Y, Shaw AM, Boules M, Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). J Pharmacol Exp Ther 2008;327:573-83
   PubMed Web of Science ®Google Scholar
• Bannwart LM, Carter DS, Cai HY, Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett 2008;18:6062-6
   PubMed Web of Science ®Google Scholar
• Carter DS, Cai HY, Lee EK, 2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression. Bioorg Med Chem Lett 2010;20:3941-5
   PubMed Web of Science ®Google Scholar
• Micheli F, Cavanni P, Andreotti D, 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem 2010;53:4989-5001
   PubMed Web of Science ®Google Scholar
• Micheli F, Cavanni P, Arban R, 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. J Med Chem 2010;53:2534-51
   PubMed Web of Science ®Google Scholar
• Hill ER, Tian J, Tilley MR, Potencies of cocaine methiodide on major cocaine targets in mice. PLoS One 2009;4:1-6
   Google Scholar
• Sanchez C, Bergqvist PB, Brennum LT, Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacol 2003;167:353-62
   PubMed Web of Science ®Google Scholar
• Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999;19:467-89
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 2001;298:565-80
   PubMed Web of Science ®Google Scholar
• Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-58
   PubMed Web of Science ®Google Scholar
• Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005;8:1481-9
   PubMed Web of Science ®Google Scholar